Back to Results
First PageMeta Content
Electroconvulsive therapy / Neurotechnology / Treatment of bipolar disorder / Linda Andre / Stefan P. Kruszewski / Major depressive disorder / Pfizer / Olanzapine / Psychiatry / Medicine / Health


International Journal of Risk & Safety in Medicine[removed]–173 DOI[removed]JRS[removed]IOS Press 171
Add to Reading List

Document Date: 2013-04-22 18:08:24


Open Document

File Size: 38,88 KB

Share Result on Facebook

Company

Eli Lilly / GlaxoSmithKline / Pfizer Inc. / Wallace Labs / Johnson and Johnson / IOS Press / Rutgers University Press / GE-Amersham Biosciences / Wyeth / AstraZeneca / Janssen Book Review 173 / /

Country

United States / /

Currency

USD / /

/

Event

Product Issues / /

/

IndustryTerm

healthcare industry / pharmaceutical / /

MedicalCondition

hyperglycemia / hyperlipidemia / injury / hyperprolactinemia / extrapyramidal side-effects / treatment-resistant depression / /

MedicalTreatment

electroconvulsive therapy / /

Organization

Duke University / US Supreme Court / Rutgers University / Eli Lilly Northeast Advisory Panel / /

Person

Linda Andre / Stefan P. Kruszewski / /

/

Position

author / speaker / /

Product

olanzapine / Neurontin / gabapentin / Paxil / Franklin / OxyContin / Zyprexa / science / /

SocialTag